Assessment of adjuvant trastuzumab-associated cardiac toxicity in Korean patients with breast cancer: A single-center analysis

Oncology (Switzerland)

Volumn 85, Issue 4, 2013, Pages 228-234

  Cha, Chihwan ^a   Ahn, Sung Gwe ^a   Lee, Hak Min ^a   Lee, Hak Woo ^a   Lee, Seung Ah ^b   Jeong, Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Eulji General Hospital   (South Korea)

Author keywords

Adjuvant treatment; Breast cancer; Cardiac toxicity; Trastuzumab

Indexed keywords

TRASTUZUMAB; ANTHRACYCLINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CARDIOTOXICITY; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; THERAPY DELAY; AGE; BODY MASS; CANCER ADJUVANT THERAPY; DIABETES MELLITUS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HYPERTENSION; MAINTENANCE DRUG DOSE; PATIENT HISTORY OF CHEMOTHERAPY; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84888220825     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354836     Document Type: Article

References (20)

1. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D: Neu/erbb-2 amplification identifies a poorprognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340-1349.
2. Burandt E, Sauter G: HER-2 ASCO guidelines. The answer to everything (in German) Pathologe 2010; 31(suppl 2):285-291.
3. Owens MA, Horten BC, Da Silva MM: HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-69.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J: Adjuvant trastuzumab in HER-2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
8. Ewer SM, Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31: 459-467.
9. Pugatsch T, Abedat S, Lotan C, Beeri R: Antierbb2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 2006; 8:R35.
10. Cook-Bruns N: Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61(suppl 2):58-66.
11. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkio S, Moykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009; 27: 5685-5692.
12. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ: Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
13. Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F, Ceccherini R, Bovelli D, Lestuzzi C, Cioffi G: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 2012; 23: 3058-3063.
14. Lee JH, Yim SH, Won YJ, Jung KW, Son BH, Lee HD, Lee ES, Yoo KY, Ahn SH, Shin HR: Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci 2007; 22(suppl):S11-S16.
15. Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, Hwang UK, Yoon HS, Ahn SH: Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 2006; 141: 155-160.
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, Mc-Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor-2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
17. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ: Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol 2010; 28: 3422-3428.
18. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor-2-positive breast cancer. J Clin Oncol 2012; 30: 3792-3799.
19. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
20. Van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, Atkinson P, Deman P, Wackers FJ: Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996; 77: 843-850.